Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab
- 13 March 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 19 (3), 274-282
- https://doi.org/10.2310/7750.2014.14092
Abstract
Background Rituximab (RTX) is increasingly used for the treatment of pemphigus and pemphigoid disorders. The high cost of RTX frequently limits its use and access. Objective To determine the health system resources and costs associated with RTX treatment of pemphigus and pemphigoid. Methods Health system resources and costs attributed to a convenience sample of 89 patients with either pemphigus or pemphigoid were identified, quantified, and valued 6 months prior to and following RTX initiation between May 2006 and August 2012. Overall cohort costs and costs per patient were calculated (2013 Can$). Results The overall cohort cost for 6 months pre-RTX was $3.8 million and for 6 months post-RTX was $2.6 million. The average cost per patient decreased from $42,231 to $29,423 (30.3% decrease). The main cost driver was intravenous immunoglobulin. Conclusions Our findings suggest that RTX is effective in reducing health system resources and the costs associated with the treatment of pemphigus and pemphigoid.Keywords
This publication has 13 references indexed in Scilit:
- Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 casesJournal of Dermatological Treatment, 2013
- Rituximab in the Treatment of Pemphigus VulgarisDermatology and Therapy, 2012
- Cost–effectiveness of rituximab in follicular lymphomaExpert Review of Pharmacoeconomics & Outcomes Research, 2012
- Pemphigoid diseases: Pathogenesis, diagnosis, and treatmentAutoimmunity, 2011
- Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)Clinics in Dermatology, 2011
- Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast CancerCurrent Oncology, 2010
- A review of the current use of rituximab in autoimmune diseasesInternational Immunopharmacology, 2009
- Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseasesInternational Immunopharmacology, 2006
- Cost of Intravenous Immunoglobulin Therapy Versus Conventional Immunosuppressive Therapy in Patients with Mucous Membrane Pemphigoid: A Preliminary StudyAnnals of Pharmacotherapy, 2005
- The Adjuvant Therapy of PemphigusArchives of Dermatology, 1996